| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $2.5M | 0.00% | 226.40K | −26% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PHAT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 21, 2026 | Parikh AsitDirector | Stock Gift at price 0.00 per share. | 28K | — |
| May 19, 2026 | Parikh AsitDirector | Conversion of Exercise of derivative security at price 4.95 per share. | 17.5K | $86.63K |
| May 18, 2026 | Fields-Kunz HeidiDirector | Stock Award(Grant) at price 0.00 per share. | 24.1K | — |
| May 18, 2026 | Karbe Frank LDirector | Stock Award(Grant) at price 0.00 per share. | 24.1K | — |
| May 18, 2026 | Topper James NDirector and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.00 per share. | 24.1K | — |
| May 18, 2026 | Schroeder Theodore RDirector | Stock Award(Grant) at price 0.00 per share. | 24.1K | — |
| May 18, 2026 | Stenhouse MarkDirector | Stock Award(Grant) at price 0.00 per share. | 24.1K | — |
| May 18, 2026 | Cola Michael FDirector | Stock Award(Grant) at price 0.00 per share. | 24.1K | — |
| May 18, 2026 | Parikh AsitDirector | Stock Award(Grant) at price 0.00 per share. | 24.1K | — |
| Mar 9, 2026 | Parikh AsitDirector | Stock Gift at price 0.00 per share. | 40K | — |
| Feb 26, 2026 | Breedlove Robert CharlesOfficer | Stock Award(Grant) at price 0.00 per share. | 15.8K | — |
| Feb 9, 2026 | Basta Steven LChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 12.4K | — |
| Feb 9, 2026 | Cook Anne MarieOfficer | Stock Award(Grant) at price 0.00 per share. | 3.5K | — |
| Jan 22, 2026 | Parikh AsitDirector | Stock Gift at price 0.00 per share. | 80.5K | — |
| Jan 12, 2026 | Parikh AsitDirector | Conversion of Exercise of derivative security at price 10.30 per share. | 8.8K | $90.13K |
| Jan 1, 2026 | Basta Steven LOfficer and Director | Stock Award(Grant) at price 0.00 per share. | 251K | — |
| Jan 1, 2026 | Cook Anne MarieOfficer | Stock Award(Grant) at price 0.00 per share. | 75.3K | — |
| Jan 1, 2026 | Narula SanjeevChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 82.7K | — |
| Dec 18, 2025 | Parikh AsitDirector | Conversion of Exercise of derivative security at price 10.30 per share. | 8.8K | $90.13K |
| Dec 16, 2025 | Basta Steven LChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 62K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -17.6 | -8.1 | -11.5 | 0.8 | -14.4 | 13.1 | -19.4 | 9.4 | -23.7 | -4.5 | −58.0% | ||
| 2025 | -26.2 | -7.8 | 13.6 | -31.6 | -0.9 | 125.6 | -10.9 | 42.6 | -3.4 | 15.1 | 15.3 | 6.2 | +104.3% |
| 2024 | -26.6 | 59.7 | -0.7 | -15.0 | 4.3 | 9.3 | 14.8 | 39.8 | 9.4 | -5.1 | -48.3 | -8.5 | −11.1% |
| 2023 | 6.3 | -28.2 | -16.6 | 49.9 | 9.9 | 21.8 | 6.2 | -5.4 | -27.9 | -10.3 | -24.8 | 30.6 | −18.6% |
| 2022 | -14.6 | 7.9 | -24.9 | -4.9 | -44.6 | 17.7 | 9.1 | -7.3 | 29.7 | -4.3 | -5.8 | 12.4 | −43.0% |
| 2021 | 15.9 | 14.4 | -14.7 | 2.6 | -8.2 | -4.2 | -5.2 | 10.9 | -9.8 | -26.7 | -23.8 | 9.6 | −40.8% |
| 2020 | 7.2 | 8.2 | -28.5 | 31.1 | 24.9 | -22.2 | 1.1 | 10.5 | -0.2 | 7.3 | 8.8 | -22.4 | +6.7% |
| 2019 | 8.4 | 21.6 | +31.8% |
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Buy / hold / sell counts